Our leadership

Shlomi Pilo brings decades of commercial, operating and business-development experience to Raphael Pharmaceutical. His background includes senior sales and marketing leadership and the development of international business relationships across multiple markets. Prior to leading Raphael, he spent many years in sales and marketing leadership at Alle Processing Corporation during a period of substantial company growth and also built experience representing manufacturers and developing cross-border commercial relationships. At Raphael, Pilo leads corporate strategy, business development and the company’s effort to translate its cannabinoid research experience into disciplined scientific and commercial opportunities. As Chairman, he also helps guide the company’s public-company strategy, governance priorities and long-term direction.

Uri Tadelis brings experience across corporate finance, investment strategy, international transactions and financial technology. His professional background has included work with institutions, banks, family offices and private clients across foreign exchange, commodities, structured investments and cross-border financial opportunities, as well as leadership in financial and technology ventures. At Raphael, Tadelis is responsible for financial oversight, reporting, capital planning and supporting the company’s investor and corporate-finance strategy as it advances its next stage of scientific and commercial development. His profile emphasizes disciplined financial stewardship, transparent public-company reporting and the connection between capital planning and Raphael’s operating priorities.

Dr. Igal Louria-Hayon is a biomedical researcher whose work has focused on immunology, cancer biology, cannabinoid science and translational research. His scientific background includes research leadership associated with Rambam Health Care Campus, including work involving medical-cannabis research and immunotherapy-related investigation. Within Raphael’s scientific platform, his role has centered on scientific strategy, biological mechanisms and the development of research programs examining purified cannabinoids, receptor biology, immune-cell communication and inflammatory pathways. His exact current corporate and advisory titles remain subject to company confirmation; institutional relationships are not endorsements.

Zvi Laufer brings legal, commercial and board experience to Raphael’s Board roster. Company materials describe a law degree from the Hebrew University of Jerusalem, admission to the Israeli Bar in 1979 and the establishment of a private law practice focused on civil and commercial matters and litigation. His background also includes public-company board service and international business experience. His contribution to Raphael is presented in the context of governance, strategic oversight and corporate development. Current appointment and committee responsibilities remain subject to company confirmation.

Prof. Joseph Press, MD, contributes medical, clinical and scientific perspective to Raphael’s scientific advisory profile. Raphael’s company materials identify him as a Science Advisor and describe his former leadership of Schneider Children’s Medical Center of Israel. His background connects clinical practice and hospital leadership with the evaluation of research opportunities. The advisory profile reflects clinical and scientific expertise relevant to the company’s research strategy; it does not imply current employment, Board membership or institutional endorsement.

Dr. Shachar Eduardo is identified in Raphael’s scientific-team materials in connection with clinical research and the Scientific Advisory Board. His clinical-research perspective is associated with Raphael’s rheumatoid-arthritis research history and the evaluation and execution of study work. The company’s source record links this role with Rambam. The profile describes that documented research context without treating historical participation as a confirmed ongoing operational appointment. The profile is limited to the documented research relationship and does not imply a current institutional appointment.

Prof. Alexandra Balbir-Gurman brings rheumatology, inflammatory-disease and clinical-research experience to Raphael’s scientific advisory profile. Company materials connect her clinical-research perspective with the rheumatoid-arthritis research program and the Scientific Advisory Board. Her experience at Rambam provides relevant context for reviewing research questions concerning inflammatory disease and patient outcomes. This profile describes the documented scientific connection without implying institutional endorsement. Current title, affiliation and scope of involvement remain subject to company confirmation; no institutional endorsement is implied.